Cdx2 Inhibitors
Cdx2 inhibitors belong to a distinct chemical class characterized by their ability to target and modulate the activity of the Caudal-type homeobox transcription factor 2, abbreviated as Cdx2. Cdx2 is a vital transcription factor that plays a fundamental role in embryonic development and tissue differentiation, particularly in the formation of the intestinal epithelium. It is primarily known for its role in the specification and maintenance of the intestinal phenotype, as well as regulating the expression of genes associated with intestinal development and function. Consequently, Cdx2 inhibitors have garnered significant interest in the field of molecular biology and developmental biology due to their potential to interfere with Cdx2-mediated processes.
The mechanism of action of Cdx2 inhibitors involves binding to Cdx2 protein or interfering with its transcriptional activity. By doing so, these inhibitors can disrupt the downstream signaling cascades and gene expression patterns regulated by Cdx2, which has far-reaching consequences in terms of cellular differentiation and development. Research into Cdx2 inhibitors has provided valuable insights into the molecular mechanisms governing gastrointestinal development and has the potential to yield applications in various scientific domains, such as regenerative medicine and stem cell research. Understanding the intricacies of Cdx2 inhibition may shed light on novel approaches for manipulating cellular fate and tissue engineering, although further research is needed to fully unlock the possibilities within this chemical class.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib inhibits CDK2 by binding to cyclin D-CDK4/6 complexes, blocking the phosphorylation of Rb, thus halting cell cycle progression. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib targets CDK4/6 and inhibits their activity, leading to cell cycle arrest in the G1 phase, blocking cancer cell proliferation. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib inhibits CDK4/6, disrupting cell cycle progression and preventing tumor cell proliferation. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib is a potent CDK inhibitor that blocks CDK2 and other CDKs, leading to cell cycle arrest and apoptosis in cancer cells. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Seliciclib is a CDK2 inhibitor that interferes with cell cycle progression, particularly in cancer cells, resulting in growth arrest. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Milciclib is a CDK2 inhibitor that halts cell cycle progression, potentially delaying tumor growth and promoting apoptosis. | ||||||
P276-00 | 920113-03-7 | sc-477932 | 1 mg | $380.00 | ||
P276-00 inhibits CDK2 and CDK4, leading to cell cycle arrest, reduced tumor cell proliferation, and potential apoptosis induction. | ||||||
NU 6140 | 444723-13-1 | sc-202531 | 5 mg | $147.00 | 1 | |
NU6140 is a CDK2 inhibitor that disrupts cell cycle progression, making it a candidate for anti-cancer therapy. | ||||||
CVT-313 | 199986-75-9 | sc-221445 sc-221445A sc-221445B | 1 mg 5 mg 50 mg | $104.00 $416.00 $2601.00 | 17 | |
CVT-313 inhibits CDK2 and interferes with cell cycle progression, potentially suppressing tumor growth. | ||||||
Zotiraciclib | 937270-47-8 | sc-507450 | 10 mg | $202.00 | ||
This compound, also called TG-02, inhibits CDK2 and other CDKs, preventing cell cycle progression and promoting apoptosis in cancer cells. | ||||||